Gilead Science's Falls Most in Almost Three Months

The video discusses the financial and market implications of high drug costs, focusing on Gilead's hepatitis C drug Harvoni, which missed sales estimates due to increased rebates and market misestimation. The impact on the biotech sector is analyzed, highlighting Gilead's influence as a bellwether stock. Additionally, Celgene's REVLIMID trial results are reviewed, noting the failure to meet a key survival endpoint, which affected its stock performance.

What were the two different endpoints of the study mentioned in the text?

Why was the stock down significantly after the interim analysis of Celgene's study?